Reverse seroconversion (RS) of Hepatitis B virus (HBV) has been reported after allogeneic transplantation with an incidence of 14% to 86%. However, most prior studies on HBV RS were performed in HBV nonendemic areas. In this study, the frequency of HBV RS at a single center in Korea, endemic for HBV, was evaluated. Also, the influence of the donor's immunity for HBV on posttransplantation HBV serologic changes in recipients was also investigated. A total of 288 patients underwent allogeneic transplantation between February 1996 and June 2008. We retrospectively reviewed the medical records of 288 patients and their paired donors. Among the 268 HBsAg(2) patients, 205 were assessed for posttransplantation HBsAg, and 114 (55.6%) of 205 had HBcAb before transplantation. With a median follow-up of 77.9 months, 3 of 114 patients experienced HBV RS (2.6%). With regard to donor immunity, significantly more patients with anti-HBs(2) donors experienced anti-HBs loss (P 5 .006), and the donor anti-HBs showed significant protective effects against the anti-HBs loss with an HR of 0.4. HBV RS after allogeneic transplantation may not be as common in HBV endemic areas. Also, donor anti-HBs showed a significant favorable effect on maintaining HBV immunity in recipients.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) accompanied by intensive chemotherapy and immunosuppression can cause immune dysfunction, which is associated with infectious complications including viral infection [1] . Hepatitis B virus (HBV) infection is 1 of the most common viral infections in humans. More than 2 billion individuals worldwide have been exposed to HBV, and more than 350 million persons are HBsAg carriers, the main reservoir of hepatitis B in human beings [2] . HBV reactivation after allogeneic HSCT (allo-HSCT) is a possible complication in patients with HBsAg before transplantation, and may lead to hepatic complications [3] [4] [5] . In addition, posttransplantation HBV reactivation in patients with negative HBsAg, but with positive anti-HBsAb and/or anti-HBcAb before transplantation, referred to as HBV reverse seroconversion (RS), has also been reported as a complication of allogeneic HSCT (allo-HSCT) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The reported frequency of RS varies from 14% to 86% based on a small number of patients. However, most prior studies on HBV RS were performed in HBV nonendemic areas.
There are several data showing that the transfer of donor immunity by way of allogeneic HSCT (allo-HSCT) may affect the posttransplantation recipient immunity against HBV [6, 7, [19] [20] [21] [22] . Clearance of HBsAg after transplantation from immune donors has been observed in patients with chronic HBV infection [19, 20] . A previous analysis reported no HBV reactivation occurred among 7 patients with anti-HBs-positive donors, whereas 4 of 30 patients without anti-HBs donors experienced HBV RS [6] , and the absence of HBsAb in a donor is reportedly a risk factor for HBV RS after HSCT [6, 7] . Furthermore, there was a report that the elective immune transfer by donor vaccine leads to spontaneous recovery of HBV immunity and the memory response in recipients [21] . Based on these results, HBV vaccination of donors was expected to play a positive role in preventing HBV reactivation in recipients. By contrast, another study reported no significant effect of the donor's vaccinated immunity on maintenance of positive HBsAb in recipients [23] .
In this study, we evaluated serologic changes of HBV in patients after allogeneic HSCT (allo-HSCT) and examined the cumulative incidence of HBV RS at a single center in Korea, where HBV infection is endemic. In addition, the effect of the donor's immunity for HBV on the posttransplantation HBV serologic status of recipients was examined.
PATIENTS AND METHODS

Patients: Recipients and Donors
A total of 289 patients underwent allogeneic HSCT (allo-HSCT) between February 1996 and June 2008 at our institution. HCV and HIV serologic markers were also evaluated in all patients; 1 patient who had HCV infection before transplantation was excluded from the analysis. Baseline information on the patients and complications during the course of the transplantation were obtained retrospectively from review of the medical records and the bone marrow transplantation (BMT) database of 288 recipients and their donors.
Hepatitis B Markers
All patients were tested for HBV infection before allogeneic HSCT (allo-HSCT), in accordance with pretransplantation protocol. HBsAg, anti-HBs, and anti-HBc were tested routinely as indicators of HBV infection. Similarly, all stem cell donors were supposed to be routinely tested for HBsAg, anti-HBs, and anti-HBc. However, because of the retrospective nature of this study, the data collection was not complete. Assessment of the HBV status was usually performed at 1 year after transplantation for patients who no longer required immunosuppression, after which, the patients without anti-HBs received HBV vaccination. For the patients with elevated liver function tests who were suspicious for hepatitis, the HBV serology was tested earlier than 1 year. Tests were delayed for patients who were under the immunosuppressive treatment because of chronic graft-versus-host disease (cGVHD) without signs of hepatitis. Patients who died before testing could not be evaluated.
Serum measurements of HBV serology was performed using different assays during the study period. Measurements of HBsAg, anti-HBs, and anti-HBc were performed using the ECLIA (electrochemiluminescence immunoassay) or IRMA (immunoradiometric assay) method. All determinations were assessed qualitatively except for the anti-HBs, which was measured by quantitative and/or qualitative IRMA. Although the titer of anti-HBs could be assessed in some patients, the status of anti-HBs was classified as either positive or negative, because some of the patients had no quantitative information available on their antibody titers.
Definition and Terminology
HBV RS was defined as the appearance of HBsAg after allo-HSCT in patients who had no HBsAg but did have anti-HBs or anti-HBc before transplantation. Transplantation conditioning regimens were classified into myeloablative (MA) and reducedintensity (RIC) based on the conditioning agents used. During the study period, BuCy (Busulfan and cyclophophamide), Cy/TBI (cyclophosphamide and TBI), VCT (etoposide, cyclophosphamide, and TBI), and Cy/ATG (cyclophosphamide and antithymocyte globulin) were the MA regimens frequently used, and Flu/Mel (fludarabine and melphalan) was typically used as the RIC regimen.
Antiviral Prophylaxis
Antiviral prophylaxis was performed for patients with positive HBsAg before allo-HSCT using lamivudine. Patients with anti HBc, but not with HBsAg were not targets of antiviral prophylaxis.
Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) v.17.0 (SPSS Inc., Chicago, IL). The cumulative probability of HBV RS and posttransplant HBsAb disappearance were calculated by Kaplan-Meier method. Risk factors for RS and anti-HBs loss were compared by chi-square or Fisher exact test where appropriate. For identification of risk factors that influenced the posttransplant anti-HBs loss, both univariate and multivariate Cox proportional hazard model was used, and the hazard ratio (HR) and 95% confidence interval (CI) were determined for all of the covariates that were shown to be statistically significant.
RESULTS
Baseline HBV Serologic Status in Recipients and Donors
The pretransplantation HBV serologic status of recipients and donors are presented in Tables 1-1 and 1-2. HBsAg and anti-HBs were examined in all 288 patients before transplantation; 20 recipients were positive for HBsAg and 268 recipients were negative for HBsAg. Among the 268 patients negative for HBsAg before transplantation, the proportion of positive anti-HBs was 89.6% (240 of 268 patients). Of the 268 patients, all but 12 patients were assessed for antiHBc before allo-HSCT; 148 patients (57.8%) had anti-HBc, whereas the remaining 108 (42.2%) patients did not. Among the 288 donors, the number of cases that had information about the HBsAg status was 255. Of these 255 donors, 249 were negative for HBsAg and 6 were positive for HBsAg. Among 249 donors negative for HBsAg before transplantation, 224 cases were assessed for anti-HBs and 213 cases were assessed for anti-HBc; 132 donors (58.9%) had anti-HBs and 70 donors (32.9%) were positive for anti-HBc before transplantation.
Pre-and Posttransplantation Characteristics of HBsAg (2) Recipients
Of the 268 patients who were negative for HBsAg before transplantation, 205 patients were assessed for the posttransplantation HBsAg status at least 1 time. Of these 205 patients, 185 patients had anti HBs and/or anti HBc before transplantation. With a median follow-up period of 77.9 months (range: 21.0-168.4), 3 of 185 patients had HBV RS. Table 2 shows the preand posttransplantation characteristics of the 185 patients. Statistical analysis was performed to compare the 2 groups; however, the results were considered to be of no value, because the number of patients who experienced HBV RS was only 3. The median age of the patients at the time of HSCT was 35 (15-64), and there were more men than women in this patient group. Acute leukemia was the most common reason for the allo-HSCT, and myeloablative conditioning regimens were more frequently used. After excluding the patients who died within 100 days of transplantation, information about cGVHD was obtained in 177 patients; 87 patients (49%) had extensive cGVHD. Among 185 patients, 114 (64%) had anti-HBc before transplantation. The characteristics of 3 recipients with HBV-RS are presented in Table 3 . All 3 patients with HBV RS had anti-HBc and anti-HBs before transplantation. Among the paired donors of these 3 recipients, 2 had complete information about their HBV serologic status including HBsAg, anti-HBs, and antiHBc, and both of them were negative for HBsAg and anti-HBs. The cumulative incidence of HBV RS was 1.6% among all 185 patients, and 2.6% among the 114 patients at risk who had resolved HBV infection before transplantation identified as positive HBcAb and negative HBsAg. The cumulative probability of HBV reactivation at 6 years (73 months) in the at-risk group was 4.8%.
HBsAb Loss after allo-HSCT According to the Donor's Immunity
All 268 patients with negative HBsAg before transplantation were assessed for pretransplantation HBsAb, and among them, 203 patients had their post-anti-HBs status determined after allo-HSCT, at least 1 time. Of these 203 patients, 181 had anti-HBs before allo-HSCT. The patients were classified by their pretransplantation anti-HBs status and further sorted by their posttransplantation anti-HBs status. Table 4 shows the pre-and posttransplantation changes in the anti-HBs in 181 patients who had positive anti-HBs before transplantation. After a median follow-up period of 76.3 months (range: 21-168), 125 patients maintained their immunity for HBV, whereas 56 patients lost their immunity. The cumulative probability of loss of anti-HBs at 6 years after transplantation was 49.6%. There was no difference in the loss or maintenance of the anti-HBs based on pretransplantation characteristics including age, sex, reason for transplantation, conditioning regimen, donor relatedness, and stem cell source. The development of extensive cGVHD was assessed in 174 of 181 patients; the presence of extensive cGVHD showed a statistically significant difference between the 2 groups (P 5 .04). The pretransplantation anti-HBc in recipients was also assessed; there was no difference in the loss of HBsAb based on pretransplantation anti-HBc in recipients. In addition, the influence of the donors' HBV serologic status on the change in the cumulative incidence of posttransplantation anti-HBs was evaluated. There was no difference in the incidence of anti-HBs loss according to the donor's HBcAb status; however, significantly more patients with nonimmunized donors (donors without anti-HBs) experienced anti-HBs loss compared with recipients with donors who had anti-HBs.
To determine risk factors associated with the loss of anti-HBs after allo-HSCT, Cox proportional hazard model was used. A total of 129 patients were finally included in this analysis, after excluding 52 patients who had insufficient data for inclusion in the study such as death before evaluation of cGVHD or insufficient HBV serology. Both univariate and multivariate analyses were performed, and the results are listed in Table 5 . Extensive cGVHD and donor anti-HBsAb retained their significance by both analyses. Patients who experienced extensive cGVHD had an adjusted HR 3.0 (P 5 .004) compared with the patient who did not. In addition, the donor anti-HBs showed significant protective effect against the loss of anti-HBs with an HR of 0.4 (P 5 .011).
HBsAb Acquisition after allo-HSCT According to the Donor's Immunity
Of the above-mentioned 203 patients assessed for their posttransplantation anti-HBs status, 22 patients did not have anti-HBs before the allo-HSCT. Among these 22 patients, 4 patients did not have information about donor immunity, and 2 patients received vaccinations before the first evaluation of anti-HBs during the posttransplantation period. The remaining 16 patients included 9 patients with donors who had no anti-HBs and 7 patients with donors who had anti- 
DISCUSSION
This retrospective study evaluated HBV RS in a large patient group in a country where HBV infection is endemic. During a median follow-up period of 77.9 months, the cumulative incidence of HBV RS was 1.6% (3 of 185) among the patients who had anti-HBs and/or anti-HBc before transplantation, and 2.6% (3 of 114) among the patients at risk who had resolved HBV infection before transplantation identified as 
HSCT indicates hematopoietic stem cell transplanation; HPV RS, hepatitis B reverse seroconversion. positive HBcAb and negative HBsAg. In addition, the cumulative probability at 6 years after transplantation was 3.7% among the patients with resolved HBV infection. RS of HBV has been reported as a late complication of HSCT. The incidence of HBV RS based on the findings of a number of studies has varied from 14% to 86%. According to the results of a recent large study, the cumulative probability at 4 years after allo-HSCT was 43% [24] . Compared with previous reports, the frequency and probability of HBV RS in this study was significantly lower (Table 6) . Korea is a country with endemic HBV infection. According to the National Health and Nutrition Survey of 1998 [25] , HBsAg seropositivity in Korea was present in 5.1% of men and 4.1% of women. Although the prevalence of HBsAg has been decreasing since the 1980s, because of the availability of vaccinations, Korea remains an area endemic for HBV. This was reflected in the patient group of this study. Among all patients, HBsAg seropositivity was present in 6.9%, and 57.8% of the patients had evidence of resolved HBV infection before transplantation. However, the proportion of patients with a history of resolved HBV infection was only 4.4% in a study conducted in the United States [24] . Given that the incidence of HBV RS in a study conducted in the United States was 19.7%, the incidence of HBV RS present in this study was very low: only 2.6% among the patients at risk. These findings illustrate the different epidemiology for HBV infection between endemic and nonendemic regions, and consequently, suggest to us that the data from nonendemic regions might significantly differ from the data collected in endemic regions. In addition, it seems that HBV reactivation after allo-HSCT is a less common complication in HBV endemic areas.
With regard to the clinical characteristics of the patients before and after transplantation, there was no significant difference between the findings from this institution and the findings from other institutions previously reported. We do not know exactly where the difference originated. There may have been some differences in treatment protocols among the different centers. For example, during the posttransplantation follow-up period, immediate vaccination of recipients is performed at this center at the time when the patients are recognized to have no immunity for HBV. In addition, it could be possible to think that the difference is partly because different regions likely have different rates of immunity for HBV. To generalize and confirm the low incidence of HBV RS in the endemic area, the first thing to check is the incidence of reverse seroconversion in other institutions in Korea as well as institutions in other endemic areas for HBV such as China and other parts of Asia, except Japan where prevalence of HBV surface antigen is relatively low. The important thing we have to notice is that the vaccination has been mandatorily recommended since the 1980s in Korea, and active HBV prophylaxis targeting newborns with HBsAg(1) parents are conducted now. After 5 to 10 years, it will be helpful to reevaluate HBV RS aimed at patients of the postvaccination era with the understanding that the change in epidemiology of HBV infection can influence the rate of HBV RS. However, the reason why HBV reactivation after allo-HSCT in the endemic area was quite low remains unclear. Other HBV serologic changes, such as the loss of anti-HBs, have been reported as well as HBV RS [10, 23] . Although it seems that recipient-derived humoral immunity would have a protective effect against HBV reactivation after allo-HSCT [24] , it has been suggested that the loss of previous HBV immunity might be inevitable as a result of the gradual loss of the recipient's immune cells in combination with the prolonged inadequate T cell-dependent B cell responses [26, 27] . Similarly, several groups have reported a tendency for the decline in the anti-HBs level after transplantation, which may be associated with the increased susceptibility to HBV reactivation [10, 28] . The 3 patients in this study who experienced HBV RS also had loss of anti-HBs when they were identified as having HBV reactivation. These findings emphasize the importance of the maintenance of HBV immunity for the prevention of HBV reactivation.
However, the information on anti-HBs loss after transplantation is limited, and is usually derived from studies with a small number of patients and with short-term follow-up [6, 7, 9, 10, 29] . In 2007, a Greek group reported on HBsAb loss during the posttransplantation period in a large cohort of 82 patients [23] . They reported that the probability of HBsAb loss was as high as 90% at 5 years. In addition, they attempted to identify risk factors that affected anti-HBs loss, and the marrow graft, ATG administration, age \30 years, and cGVHD were emphasized as significant predictive factors. With regard to donor immunity, they reported that the presence of donor immunity did not significantly influence HBsAb negativity in their patient group. In this study, the risk factors for anti-HBs loss after transplantation were also evaluated. The findings showed that donor immunity for HBV had a protective effect against the loss of anti-HBs in the recipients. When compared by the Fisher exact test and analyzed by the Cox proportional hazard model, the donors' anti-HBs continued to be a statistically significant factor. These findings are not consistent with those of the Greek study discussed above. One possible explanation for this discrepancy is the small sample size of the Greek study compared with the size of this study and the different method of categorization of donor immunity. In addition to the donors' anti-HBs status, the presence of extensive cGVHD was identified as a significant risk factor for posttransplantation anti-HBs loss by both univariate and multivariate analyses. It is very interesting that the presence of extensive cGVHD has also been designated as a risk factor for HBV RS in a previous report [24] .
With regard to vaccination, donor vaccination has been shown to improve the posttransplantation immunity of the recipient in the case of tetanus toxoid, 7-valent pneumococcal conjugate vaccine (PCV), and Haemophilus influenza type b-conjugate vaccines [30] . However, with regard to HBV, the efficacy of donor vaccination has not been well established; this issue continues to be debated [5, 6, 12, 17, 31, 32] . In this study, there was a protective effect of the donors' anti-HBs on the maintenance of the recipients' immunity for HBV; therefore, the recommendation for HBV vaccination in donors seems to be reasonable. Also, it may be perhaps that the effect of donor vaccination can be notably seen in HBV nonendemic areas where the rate of HBV RS among the patients at risk is relatively high.
The limitations of this study include the following. First, a quantitative assessment of the anti-HBs titer was not performed in all patients; therefore, it was impossible to determine the serial changes of the anti-HBs precisely. Second, the posttransplantation serum measurement of the HBV serology was not standardized. Therefore, the timing of the first examination after transplantation and the interval between each examination was varied. Third, it would be helpful in understanding a protective effect of donor immunity against HBV RS, especially in regard to type of donor immunity, if the information about prior immunization was included in this analysis. Unfortunately, we did not know the patients' or donors' histories if they were vaccinated for HBV or not before allo-HSCT. Indirectly, patients or donors with anti-HBs(1)/anti-HBc(1), or with anti-HBs(2)/anti-HBc(1), were supposed to have been exposed to previous HBV infection. In case of anti-HBs(1)/ anti-HBc(2), however, there may be a mixture of patients or donors who had immunity for HBV because of vaccination and individuals with uncomfirmed anti-HBc despite of exposure to previous HBV infection. Because of the uncertainty for source of immunity, we could not identify the benefits of transfer of donor immunity based on type of immunization.
In summary, HBV RS is a well-known late complication of allo-HSCT reported to occur in more than 10% of cases. However, the incidence of HBV RS in this study, which was performed at a single center in Korea where HBV is endemic, was only 2.6% among patients with anti-HBc before transplantation. This suggests that HBV RS after allo-HSCT may not be as common in HBV endemic areas, and that the incidence of HBV RS likely differs depending on the epidemiology for HBV infection in a given region. With regard to posttransplantation anti-HBs loss, the donor anti-HBs had a significant favorable effect on maintaining the HBV immunity of recipients with anti-HBs before transplantation. These results should serve as a basis for future studies and for developing guidelines for preventing posttransplantation HBV reactivation.
